Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Feb;25(2):83-91.
doi: 10.1007/s11912-022-01350-9. Epub 2022 Dec 26.

Novel Therapies for High-Risk Non-Muscle Invasive Bladder Cancer

Bashir Al Hussein Al Awamlh  1 , Sam S Chang  2   3
Affiliations
Review

Novel Therapies for High-Risk Non-Muscle Invasive Bladder Cancer

Bashir Al Hussein Al Awamlh et al. Curr Oncol Rep. 2023 Feb.

Abstract

Purpose of review: The treatment options for high-risk non-muscle invasive bladder cancer (NMIBC), particularly following BCG, remain limited. We highlight recent, promising therapies for high-risk NMIBC.

Recent findings: Several therapies utilizing different mechanisms of action have demonstrated favorable results in the BCG-naïve and BCG-unresponsive settings. These treatments include intravenous and intravesical immunotherapy, viral- and bacterial-based intravesical therapies, combination intravesical chemotherapy regimens, and novel intravesical chemotherapy administration. Overall, the efficacy and tolerability of emerging treatments for NMIBC appear promising and provide potential alternatives to radical cystectomy. As the landscape of managing BCG-unresponsive disease evolves, clinical trials will explore future options and determine effective alternatives.

Keywords: BCG-unresponsive; Carcinoma in situ of the bladder; Intravesical chemotherapy; Non-muscle invasive bladder cancer.

PubMed Disclaimer

Conflict of interest statement

ICMJE disclosure forms are provided. SSC has consulted for the following: Urogen, Merck, Janssen, Pfizer, and ImmunityBio. Vanderbilt University Medical Center is a trial site for TAR-200.

Figures

Fig. 1
Fig. 1
Novel treatments for high-risk non-muscle invasive bladder cancer (NMIBC)
See this image and copyright information in PMC

References

    1. Cumberbatch MGK, Jubber I, Black PC, Esperto F, Figueroa JD, Kamat AM, et al. Epidemiology of bladder cancer: a systematic review and contemporary update of risk factors in 2018. Eur Urol. 2018;74(6):784–795. doi: 10.1016/j.eururo.2018.09.001. - DOI - PubMed
    1. Bladder cancer statistics. 2020. https://www.wcrf.org/cancer-trends/bladder-cancer-statistics. Accessed 22 Aug 2022.
    1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7–33. doi: 10.3322/caac.21708. - DOI - PubMed
    1. Babjuk M, Burger M, Comperat EM, Gontero P, Mostafid AH, Palou J, et al. European Association of Urology Guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ) - 2019 Update. Eur Urol. 2019;76(5):639–657. doi: 10.1016/j.eururo.2019.08.016. - DOI - PubMed
    1. Chang SS, Boorjian SA, Chou R, Clark PE, Daneshmand S, Konety BR, et al. Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO guideline. J Urol. 2016;196(4):1021–1029. doi: 10.1016/j.juro.2016.06.049. - DOI - PubMed